
ImmunoGen Stock: Despite First Approval, They Have Many Problems (NASDAQ:IMGN)
Tara Moore/DigitalVision via Getty Images After spending 40 years in the lab, ImmunoGen (NASDAQ:IMGN) delivered its first fully owned approved product last year, but you would never know that from looking at its stock price […]